Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Clinical trial NCT07675057 · AVAILABLE

Trial details

NCT number: NCT07675057
Sponsor: Eli Lilly and Company
Status: AVAILABLE
Study type: EXPANDED_ACCESS

Urinary Bladder Neoplasms Neoplasm Metastasis Carcinoma, Transitional Cell

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.